127 related articles for article (PubMed ID: 31988438)
41. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
[TBL] [Abstract][Full Text] [Related]
42. An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.
Carter BZ; Mak PY; Wang X; Tao W; Ruvolo V; Mak D; Mu H; Burks JK; Andreeff M
Cancer Res; 2019 Mar; 79(6):1165-1177. PubMed ID: 30674535
[TBL] [Abstract][Full Text] [Related]
43. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
44. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.
Wood AC; Zhang Y; Mo Q; Cen L; Fontaine J; Hoffe SE; Frakes J; Dineen SP; Pimiento JM; Walko CM; Mehta R
Oncologist; 2022 Apr; 27(4):307-313. PubMed ID: 35380714
[TBL] [Abstract][Full Text] [Related]
46. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
48. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
49. The effect of cantharidins on leukemic stem cells.
Dorn DC; Kou CA; Png KJ; Moore MA
Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
[TBL] [Abstract][Full Text] [Related]
50. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
52. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
53. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
[TBL] [Abstract][Full Text] [Related]
54. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
56. TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
Pabst G; Lind K; Graf R; Zebisch A; Stölzel F; Döhner K; Heitzer E; Reinisch A; Sill H
Ann Hematol; 2020 Mar; 99(3):653-655. PubMed ID: 32002654
[No Abstract] [Full Text] [Related]
57. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
[TBL] [Abstract][Full Text] [Related]
58. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract][Full Text] [Related]
59. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
60. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
